AI summary · may contain errors
Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.
Moving in JAMA Oncology, Journal of Clinical Oncology, Clinical Cancer Research, JNCI: Journal of the National Cancer Institute, Frontiers in Genetics, Med, Nature Communications and Ophthalmology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.
AI summary · may contain errors
In a multicenter cohort of 6,049 nonmetastatic nasopharyngeal carcinoma patients treated with IMRT, TNM-9 improved prognostic performance over TNM-8 but left T- and N-category discrimination limited.
AI summary · may contain errors
For non-metastatic stage IB–III nasopharyngeal carcinoma, the updated CSCO-ASCO guideline strengthens definitive treatment with IMRT plus image guidance and MRI-based target delineation as core components.
AI summary · may contain errors
Platinum-based chemotherapy combined with a PD-1 inhibitor is recommended as preferred first-line systemic therapy for medically fit patients with recurrent and/or metastatic nasopharyngeal carcinoma.
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in stage III–IV HPV-negative SCCHN and stage II–III HPV-positive oropharyngeal SCCHN achieved a 45% primary-site pCR.
AI summary · may contain errors
Five-year outcomes after a de-escalated 30-Gy elective nodal irradiation regimen during definitive concurrent chemoradiotherapy are reported for patients with HPV-associated oropharyngeal carcinoma.
AI summary · may contain errors
A multi-layer reanalysis of sinonasal squamous cell carcinoma identifies a tumor-normal shift with a +44.7 percentage-point increase in epithelial cells and a +1.727 cell-cycle program change.
AI summary · may contain errors
In the REMATCH single-institution phase II trial of locally advanced head and neck cancer, 2-year disease-free survival reached 90% with universal laryngeal preservation.
AI summary · may contain errors
Response-adapted postoperative therapy after neoadjuvant sintilimab plus chemotherapy yields a 59.1% major pathologic response rate in resectable stage III–IVB LA-HNSCC.
AI summary · may contain errors
In postoperative high-risk locally advanced squamous cell carcinoma of the head and neck, weekly cisplatin achieved 5-year overall survival of 71.2% versus 58.7% with 3-weekly cisplatin.
Journals this month
Topics moving, week to 17 Nov 2026
By field